Hb22.7

N/A

Report date: 2025/03/20 15:46:22

Base Information

Drug NameHb22.7
Drug Alias Nameanti-CD22 monoclonal antibodies (University of California Davis)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCD226 antigen blockers
TargetsCD226 antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A